Skip to content

Clinical efficacy and mechanism of accelerated cTBS therapy in patients with anxiety disorder

Clinical efficacy and mechanism of accelerated cTBS therapy in patients with anxiety disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096454
Enrollment
Unknown
Registered
2025-01-24
Start date
2025-01-26
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety symptoms

Interventions

a-cTBS real stimulation group:The figure-eight stimulation coil is localized to the right dorsolateral prefrontal cortex (DLPFC), which was determined by using MNI coordinates (x,y,z =-44,40,29) in th
a-cTBS sham stimulation group:In the a-cTBS pseudo-stimulation group, the subject's operating flow is consistent with that of the true stimulation group, where the subject's head is first fixed in a s

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~65 years old; 2. Meet the diagnostic criteria for anxiety disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 3. HAMA total score >=14 points; 4. Right hand; 5. The patient's physical examination, medical history, vital signs, hematuria and stool routine, liver and kidney function, electrolytes, electrocardiogram, electroencephalogram and other indicators were normal; 6. After fully understanding the safety of transcranial magnetic stimulation (TMS), willing to actively cooperate with the treatment, and signed informed consent by the person and his family.

Exclusion criteria

Exclusion criteria: 1. Age 65 years old; 2. Have a history of severe physical illness and anxiety caused by other psychoactive substances and non-dependent substances; 3. Patients with metal or electronic devices built into their bodies, such as intracranial metal foreign bodies, cochlear implants, pacemakers, stents and other metal foreign bodies; 4. Have a risk of seizures, have previous craniocerebral diseases, head trauma, alcoholism, electroencephalogram abnormalities, MRI evidence of brain structural abnormalities, or have a family history of epilepsy; 5. Those who have psychotic symptoms and need to be combined with antipsychotic drugs; 6. Received ECT or other physical therapy within 2 months before enrollment.

Design outcomes

Primary

MeasureTime frame
Hamilton Anxiety Scale score;

Secondary

MeasureTime frame
Near Infrared Imaging (fNIRS);Resting state/task state EEG;Other scales, etc. (anxiety, suicide, cognition, etc.);Transcranial magnetoencephalography (TMS-EEG);Transcranial magneto-myography (TMS-MEP);Paired pulse stimulation;3.0T magnetic resonance imaging (MRI);

Countries

China

Contacts

Public ContactYu Chang

Affiliated Kangning Hospital of Ningbo University

272450699@qq.com+86 15888107922

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026